May 06, 2026 | Read online

Right Before the Open: (MDCX) is One to Watch This Morning

Any content you receive is for information purposes only. Always conduct your own research.

*Disseminated on Behalf of Medicus Pharma Ltd.

Market Maven Insights Puts (MDCX) Back At The Top Of This Morning’s Watchlist—Wednesday, May 6, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage Starts Right Now.

Take A Look At (MDCX) Right Now…

May 6, 2026

Dear Reader,

The shift is already happening—most people just haven’t noticed it yet.

Artificial intelligence is quietly moving from a buzzword into a real tool inside clinical development—and Medicus Pharma Ltd. (NASDAQ: MDCX) recently made a move that puts it right in that transition.

(MDCX) recently introduced an initiative to integrate AI-driven clinical data analytics across its development pipeline, beginning with its late-stage Teverelix program.

The aim is straightforward: more efficient trial execution, smarter site selection, improved patient stratification, and better use of clinical resources as programs advance.

But that update didn’t arrive on its own.

(MDCX) has already confirmed full enrollment of all 90 patients in its U.S. Phase 2 SkinJect study—marking a key milestone and positioning the company for topline data expected in Q1 2026.

Taken together, the sequence is notable: operational progress, technology integration, and a defined near-term catalyst window—all beginning to line up.

That’s what’s bringing Medicus Pharma Ltd. (MDCX) back into focus Wednesday morning, May 6, 2026.

We’ve highlighted the profile before, but the recent developments add a new layer of momentum worth watching.

Then there’s the underlying structure.

With a public float still under 10M shares, (MDCX) remains tightly held, conditions where changes in demand can have an amplified impact on price behavior.

That dynamic has already been visible. (MDCX) has shown the ability to move quickly in short timeframes, including a sharp multi-day move earlier in the quarter.

Layer in insider ownership above 30%, often seen as a sign of internal alignment, and the broader setup becomes clearer.

But keep in mind, one analyst has a target on (MDCX) that you’ll want to see.

Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group, has a $2 target on (MDCX) which suggests 700% upside potential from its recent $.25 range.

When multiple elements begin converging like this, execution milestones, new technology integration, and upcoming potential data catalysts, it tends to bring names back onto the radar.

And that’s exactly where this one is starting to sit right now.

Inside (MDCX): Advancing Next-Gen Therapeutics

Medicus Pharma Ltd. is a clinical-stage biotech and life sciences company focused on advancing novel, potentially disruptive therapeutic assets across oncology, dermatology, and hormone-related conditions. The company operates globally and centers its strategy on progressing dr-ug candidates through Phase 2 clinical development before pursuing licensing or commercialization partnerships with larger pharmaceutical companies.

At the core of its pipeline are two primary programs:

SkinJect™ Platform (Dermatology / Oncology)

SkinJect™ is a non-invasive, microneedle-based immuno-oncology therapy designed to treat basal cell carcinoma (BCC), the most common form of skin cancer. The platform uses a patented dissolvable microneedle array to deliver the chemotherapy agent doxorubicin directly into cancerous skin lesions—aiming to eliminate tumors without traditional surgery.

Focus: Non-melanoma skin cancers, including BCC and rare conditions like Gorlin Syndrome
Mechanism: Localized dr-ug delivery via dissolvable microneedles
Clinical Stage: Completed Phase 2 study with reported positive data, including meaningful lesion clearance rates

Teverelix® (Urology / Oncology)

Teverelix is a next-generation GnRH antagonist being developed for hormone-driven conditions, including advanced prostate cancer and acute urinary retention related to enlarged prostate. It is designed to suppress testosterone without the initial hormonal surge seen in traditional therapies, potentially reducing cardiovascular risk in vulnerable patients.

Focus: Advanced prostate cancer and urology indications
Differentiation: Long-acting hormone suppression with improved safety profile potential
Clinical Stage: Advancing through Phase 2/2b development with FDA-cleared studies underway

Technology & Development Strategy

Medicus is also exploring AI-driven clinical data analytics to enhance trial design, site selection, and patient stratification—aiming to improve efficiency and reduce development timelines across its pipeline.

The company’s broader model is built around:

Advancing assets through early-to-mid clinical stages
Generating proof-of-concept data
Partnering with larger pharmaceutical companies for late-stage development and commercialization

With programs targeting multi-bn-dollar markets—including prostate cancer and non-melanoma skin cancers—Medicus Pharma is positioned at the intersection of precision medicine, dr-ug delivery innovation, and data-driven clinical development.

Market Sector Potential: Targeting Large, Underserved Treatment Markets

Medicus Pharma Ltd. (NASDAQ: MDCX) is positioned across two major healthcare markets: non-melanoma skin cancer and prostate cancer/urology, both areas where treatment innovation continues to attract attention.

Its SkinJect™ platform is focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC), using localized microneedle-based delivery as a potential non-surgical treatment approach. Medicus recently described SkinJect as a “localized immuno-oncology precision product” targeting BCC and related skin diseases.

That matters because BCC is one of the most common forms of skin cancer, and the current standard of care often involves procedures such as excision, Mohs surgery, or other lesion-directed treatments. A non-invasive, lesion-targeted option could create meaningful commercial interest if clinical results continue to support the platform.

On the urology side, Medicus is advancing Teverelix®, a next-generation GnRH antagonist being developed for advanced prostate cancer patients with high cardiovascular risk and for acute urinary retention relapse prevention. The company has stated that these indications collectively represent an estimated $6B potential market.

The broader prostate cancer therapeutics market also supports the size of the potential. Global Market Insights estimated the prostate cancer therapeutics market at $12.6B in 2024, with projections reaching $29.9B by 2034, reflecting a 9.2% CAGR.

That gives (MDCX) exposure to two separate but potentially valuable lanes: a skin cancer platform aimed at localized treatment innovation, and a hormone-focused urology/prostate cancer program targeting patients with significant unmet need. If both programs continue advancing through clinical and regulatory milestones, MDCX could remain positioned within markets large enough to support meaningful partnership, licensing, or commercialization potential.

Momentum Is Building: Recent Milestones Driving the Story Forward

Recent press releases from Medicus Pharma Ltd. point to a steady cadence of clinical, regulatory, and strategic progress across its pipeline in 2026.

Phase 2 SkinJect Data Validation: The company reported independent key opinion leader (KOL) validation of its Phase 2 SkinJect study, reinforcing previously disclosed results.

Approximately 80% overall response rate (ORR)
Around 73% clinical clearance of lesions at Day 57
Data suggests potential to reduce or delay surgical intervention

These findings continue to support SkinJect as a differentiated, non-invasive treatment approach.

Orphan Dr-ug Designation Strategy Expansion: Medicus submitted an Orphan Dr-ug Designation (ODD) application to the FDA for SkinJect in Gorlin Syndrome, a rare condition with limited treatment options.

Targets patients with recurring basal cell carcinoma burden
Opens potential access to regulatory incentives and exclusivity pathways
Expands the platform into a high unmet-need indication

Teverelix Phase 2 Program Advancement: The company submitted an optimized Phase 2 study protocol to the FDA for Teverelix in acute urinary retention relapse.

Focused on efficient, mechanism-driven study design
Targets patients with benign prostatic hyperplasia (BPH)
Includes interim analysis to guide dosing and development

FDA Clearance for Phase 2b Prostate Cancer Study: Medicus received FDA “study may proceed” clearance for its Phase 2b Teverelix study in advanced prostate cancer patients with elevated cardiovascular risk.

Represents a key regulatory milestone
Expands development into a multi-bn-dollar therapeutic area
Moves Teverelix further into later-stage clinical positioning

New Clinical Data Presentation at AACE 2026: The company announced plans to present new Teverelix data at the American Association of Clinical Endocrinology (AACE) 2026 meeting.

Focus on pharmacokinetics, pharmacodynamics, and safety
Highlights broader applicability across hormone-driven conditions
Increases visibility within the clinical community

AI-Driven Clinical Development Initiative: Medicus has also outlined plans to integrate AI-driven analytics into its clinical pipeline.

Focus on improving site selection and patient stratification
Aims to enhance efficiency and reduce development timelines
Expected to support upcoming studies across the pipeline

7 Reasons Why Medicus Pharma Ltd. Is Topping Our Watchlist This Morning—Wednesday, May 6, 2026

1. Multiple Clinical Programs Advancing Simultaneously: Medicus is progressing two late-stage assets—SkinJect and Teverelix—across dermatology, oncology, and urology. That kind of multi-program pipeline adds depth and increases the number of potential inflection points.

2. Phase 2 SkinJect Data Showing Strong Signals: Recent updates highlighted meaningful response and clearance rates in the Phase 2 study, reinforcing the platform’s potential as a non-invasive treatment option in a large and common disease category.

3. Teverelix Moving Deeper Into Clinical Development: With FDA clearance to proceed on a Phase 2b study in advanced prostate cancer and additional protocol work underway, Teverelix continues to expand its role across hormone-driven conditions.

4. AI Integration Layer Now Entering the Story: The company has begun incorporating AI-driven clinical analytics into its pipeline—aimed at improving trial design, patient selection, and overall efficiency. That adds a modern development layer to the broader narrative.

5. Analyst Coverage Still Points to a Valuation Gap: Current analyst targets cluster well above recent levels, with consensus estimates suggesting multi-fold upside if execution continues and catalysts play out.

6. Tight Float Structure Creates Sensitivity to Demand: With a public float under 10M shares, (MDCX) sits in a tightly held position. Structures like this can react quickly when attention begins to build.

7. Recent Behavior Shows It Can Move Quickly: (MDCX) has already demonstrated the ability to make sharp moves in short timeframes. When that kind of behavior meets new potential catalysts, it tends to draw increased attention.

Take A Look At (MDCX) Right Now…

With multiple layers beginning to align at once, Medicus Pharma Ltd., (MDCX) is entering a more defined window—one shaped by a float still under 10M shares, a chart that has already shown the ability to move quickly, and analyst targets that continue to sit well above current levels.

Add in insider ownership above 30%, continued FDA progress across its Teverelix program, advancing Phase 2 activity, and a pipeline anchored by two late-stage assets, and it becomes easier to see why this story is starting to re-emerge.

Execution, new data, and forward potential catalysts are beginning to stack.

We have all eyes on (MDCX) this morning.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/05/2026 and ending on 05/06/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid fifty two thousand three hundred USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (MDCX:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/mdcx-vb340/#details}